March 20, 2026

FDA Clears Setmelanotide for Hypothalamic Obesity

First and only FDA-approved therapy showed an 18.4% placebo-adjusted BMI reduction at 52 weeks

Conexiant

March 19, 2026

Wegovy HD Secures FDA Approval

Semaglutide 7.2 mg achieved 20.7% mean weight loss in STEP UP trials.

Conexiant

March 19, 2026

Sleeve vs Gastric Bypass: Nutrient Intake at 1 Year

Investigators analyze 4-day food records and supplement reports from 285 patients at seven Swedish metabolic and bariatric centers in a substudy of the randomized BEST trial.

Conexiant

March 18, 2026

AAP, NASPGHAN Issue Guidance on Faltering Weight in Children

New recommendations standardize diagnosis and aim to reduce unnecessary interventions in early childhood growth concerns.

Conexiant

March 17, 2026

Teen Conflict and the Body’s Clock

Parent and peer relationship patterns across adolescence are examined alongside biomarkers of aging.

Conexiant

March 04, 2026

AI's Expanding Role in Diabetes Care

Machine learning models applied to inpatient electronic health record data have predicted insulin needs more accurately than traditional guidelines.

Conexiant

March 05, 2026

Calcium Strategy Following Thyroidectomy

Investigators compare routine prophylaxis vs postoperative parathyroid hormone-guided supplementation.

Conexiant

March 04, 2026

AI Carb Estimates From ChatGPT a Glycemic Risk?

"The findings of this study indicate that individuals living with T1D should use ChatGPT-4o to estimate carbohydrates with caution,"

Conexiant

March 02, 2026

FDA Okays Weekly Option in Achondroplasia

Navepegritide is described as the first therapy to deliver continuous C-type natriuretic peptide exposure over a weekly dosing interval in eligible pediatric patients.

Conexiant

February 26, 2026

AHA Issues Pediatric Hypertriglyceridemia Statement

The scientific statement defines pancreatitis and atherosclerotic cardiovascular disease risk thresholds and outlines causes and management in youths.

Conexiant